Eli Lilly and Co: All Recent News

• All recent news
• Earnings news

Final Glance: Pharmaceuticals companies 11/23/2009

NEW YORK (AP) - Shares of some top pharmaceuticals companies were mixed at the close of trading:... Associated Press

($) Sanofi Has Lots of Upside Catalysts 11/23/2009

Looks like the patent worries aren't so dire after all. At TheStreet.com

Worse Than You Think 11/20/2009

A look at how much of the $2.5 trillion the U.S. spends on health care goes down the drain. At Forbes

This Baby Is a Nice Addition 11/20/2009

A month into an acquisition, and Merck already sees a benefit. At Motley Fool

5 Signs of a Strong Dividend Stock 11/20/2009

Simplify your strategy. At Motley Fool

Health Fraud Caseload Grows 11/20/2009

... At Wall Street Journal

Early Glance: Pharmaceuticals companies 11/20/2009

NEW YORK (AP) - Shares of some top pharmaceuticals companies are mixed at 10 a.m.:... Associated Press

Trading Review for Vivus Inc. Issued by Beacon Equity 11/20/2009

DALLAS, Nov. 20, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Vivus Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision. GlobeNewswire

For Lilly's R&D Chief, a $2 Million Exit Handshake 11/19/2009

... At Wall Street Journal

AstraZeneca Enters the Race for the Next Plavix 11/19/2009

The pharmaceutical landscape is rapidly changing as patents for some of the blockbuster drugs of the last decade near expiration and other players try to grab some of the remaining revenues before generic medications flood the market. AstraZeneca (AZN) announced Thursday morning that it has filed a New Drug Application with the FDA for its antiplatelet treatment ticagrelor. The drug is meant to treat major cardiac events in patients with acute coronary syndrome (ACS) a disease that affects 2.4 million Americans according to the American Heart Association.The drug works by keeping platelets in... At Minyanville

Moody's gives negative view on pharma credit 11/19/2009

NEW YORK (AP) - Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent. Associated Press

Obesity and ED: Two Big Markets, One Tiny Company 11/18/2009

Vivus (VVUS) is raising the bar on erectile dysfunction drugs potentially becoming the latest formidable competitor to Viagra and Cialis in the $3.8 billion market. Investors in the California-based pharmaceutical company jumped on Wednesday when the company cited positive results from a late-stage study of its erectile dysfunction drug avanafil. The stock shot up almost 6% in early morning trading while shares of Pfizer (PFE) which makes Viagra and Eli Lilly (LLY) maker of Cialis remained relatively flat. Vivus announced the results from its phase 3 Revive study which tested the safety and... Minyanville

New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend... 11/18/2009

PARSIPPANY, N.J. and INDIANAPOLIS, Nov. 18 /PRNewswire-FirstCall/ --Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one... PR Newswire

Your Heart or Your Stomach? 11/18/2009

It won't be a tough decision for patients to make. At Motley Fool

VIVUS Gets a Spark 11/18/2009

A new erectile-dysfunction drug shows promise. At Motley Fool

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status